Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
Br J Cancer
; 118(1): 38-42, 2018 01.
Article
en En
| MEDLINE
| ID: mdl-29149104
ABSTRACT
BACKGROUND:
We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease.METHODS:
Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans.RESULTS:
At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9%). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4%) and a lower CIR of non-CNS progression (25.8 vs 42.5%). Adverse events leading to withdrawal occurred in 5.9% and 6.7% of patients with and without baseline CNS metastases, respectively.CONCLUSIONS:
This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Piperidinas
/
Carbazoles
/
Neoplasias del Sistema Nervioso Central
/
Carcinoma de Pulmón de Células no Pequeñas
/
Inhibidores de Proteínas Quinasas
/
Quinasa de Linfoma Anaplásico
/
Neoplasias Pulmonares
Tipo de estudio:
Incidence_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Br J Cancer
Año:
2018
Tipo del documento:
Article
País de afiliación:
Estados Unidos